KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Net Income (2016 - 2025)

Historic Net Income for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$20.7 million.

  • Inovio Pharmaceuticals' Net Income rose 2127.37% to -$20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.9 million, marking a year-over-year increase of 2330.59%. This contributed to the annual value of -$107.8 million for FY2024, which is 2021.03% up from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Net Income stood at -$20.7 million, which was up 2127.37% from -$22.5 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Net Income ranged from a high of -$19.5 million in Q4 2024 and a low of -$108.5 million during Q2 2022
  • Moreover, its 5-year median value for Net Income was -$35.5 million (2023), whereas its average is -$46.9 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 38746.36% in 2021, then skyrocketed by 6724.85% in 2023.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Net Income stood at -$106.9 million in 2021, then skyrocketed by 49.07% to -$54.5 million in 2022, then surged by 54.09% to -$25.0 million in 2023, then rose by 21.94% to -$19.5 million in 2024, then fell by 5.85% to -$20.7 million in 2025.
  • Its Net Income stands at -$20.7 million for Q3 2025, versus -$22.5 million for Q2 2025 and -$24.2 million for Q1 2025.